---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055791"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:45:24.680441+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q1: pro forma revenue $46.2M (+2% YoY), gross margin 49.2%, cash $464M, reaffirms FY outlook

## Summary
- As-reported revenue $45.5M (+81% YoY from SomaLogic merger); pro forma combined revenue $46.2M (+2% YoY).
- Pro forma gross margin 49.2% (up 276 bps), non-GAAP gross margin 56.3% (up 300 bps). Operating expenses fell $21M to $75.8M.
- Cash, equivalents, restricted cash & short-term investments $463.6M. Repurchased 4.1M shares for $11M; converted all Series B preferred to common.
- Reaffirmed FY2024 revenue guidance $200-205M; targeting cash flow positive in FY2026. $50M of $80M cost synergies expected by year-end 2024.
- SomaScan services, authorized sites, Illumina early access contributed over $24M (+21% YoY); instrument revenue declined 12% on capex headwinds.

## SEC filing metadata
- accession: 0000950170-24-055791
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095017024055791/0000950170-24-055791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095017024055791/lab-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055791
- JSON: https://secwatch.observer/filing/0000950170-24-055791.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055791.txt

## Key facts
- Earnings Releases
  STANDARD BIOTOOLS INC. reported the three months ended March 31, 2024 results: revenue $45.5 million, net income $(32.2) million. Guidance reaffirmed.
  - Period: the three months ended March 31, 2024
  - Revenue: $45.5 million
  - Net income: $(32.2) million
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 8, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095017024055791/0000950170-24-055791-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.